The anti-Müllerian hormone type II receptor: Insights into the binding domains recognized by a monoclonal antibody and the natural ligand

Biochemical Journal

Volumn 379, Issue 3, 2004, Pages 785-793

  Salhi, Imed ^a,b   Cambon Roques, Sylvie ^a,b   Lamarre, Isabelle ^a   Laune, Daniel ^b   Molina, Franck ^b   Pugnière, Martine ^b   Pourquier, Didier ^c   Gutowski, Marian ^a,b   Picard, Jean Yves ^a   Xavier, Françoise ^a,b   Pèlegrin, André ^a,b   Navarro Teulon, Isabelle ^a,b  

^a INSERM   (France)

^b CNRS   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

AMH type II receptor (AMHR II); Anti M llerian hormone (AMH); Peptide array; Structure modelling

Indexed keywords

BIOCHEMISTRY; BIOLOGICAL ORGANS; CELLS; CHEMICAL BONDS; ORGANIC ACIDS; TUMORS;

CHINESE-HAMSTER OVARY CELLS; TRANSFORMING GROWTH FACTOR (TGF);

MONOCLONAL ANTIBODIES;

ALANINE; ASPARTIC ACID; EPITOPE; GLYCINE; HORMONE RECEPTOR; ISOPROTEIN; LIGAND; MONOCLONAL ANTIBODY; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CROSS REACTION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; GRANULOSA CELL TUMOR; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SCREENING; TESTIS; WESTERN BLOTTING;

ALANINE; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ASPARAGINE; BINDING SITES; BLOTTING, WESTERN; CELL LINE; CHO CELLS; CRICETINAE; EPITOPE MAPPING; FLOW CYTOMETRY; GLYCOPROTEINS; GRANULOSA CELL TUMOR; HUMANS; LEYDIG CELLS; LIGANDS; MALE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, PEPTIDE; SERTOLI CELLS; TESTICULAR HORMONES;

ANIMALIA; CRICETINAE; CRICETULUS GRISEUS; MURINAE;

EID: 2542585351     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20031961     Document Type: Article

References (54)

1. Vigier, B., Picard, J. Y., Tran, D., Legeai, L. and Josso, N. (1984) Production of anti-Mullerian hormone: another homology between Sertoli and granulosa cells. Endocrinology 114, 1315-1320
2. Josso, N., Lamarre, I., Picard, J. Y., Berta, P., Davies, N., Morichon, N., Peschanski, M. and Jeny, R. (1993) Anti-Mullerian hormone in early human development. Early Hum. Dev. 33, 91-99
3. Lee, M. M. and Donahoe, P. K. (1993) Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocr. Rev. 14, 152-164
4. Jost, A., Vigier, B. and Prepin, J. (1972) Freemartins in cattle: the first steps of sexual organogenesis. J. Reprod. Fertil. 29, 349-379
5. Behringer, R. R., Cate, R. L., Froelick, G. J., Palmiter, R. D. and Brinster, R. L. (1990) Abnormal sexual development intransgenic mice chronically expressing Mullerian inhibiting substance. Nature (London) 345, 167-170
6. Mishina, Y., Rey, R., Finegold, M. J., Matzuk, M. M., Josso, N., Cate, R. L. and Behringer, R. R. (1996) Genetic analysis of the Mullerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes Dev. 10, 2577-2587
7. Josso, N., Racine, C., di Clemente, N., Rey, R. and Xavier, F. (1998) The role of anti-Mullerian hormone in gonadal development. Mol. Cell. Endocrinol. 145, 3-7
8. Teixeira, J., Maheswaran, S. and Donahoe, P. K. (2001) Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr. Rev. 22, 657-674
9. Segev, D. L., Hoshiya, Y., Hoshiya, M., Tran, T. T., Carey, J. L., Stephen, A. E., MacLaughlin, D. T., Donahoe, P. K. and Maheswaran, S. (2002) Mullerian-inhibiting substance regulates NF-κB signaling in the prostate in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 99, 239-244
10. Masiakos, P. T., MacLaughlin, D. T., Maheswaran, S., Teixeira, J., Fuller, Jr, A. F., Shah, P. C., Kehas, D. J., Kenneally, M. K., Dombkowski, D. M., Ha, T. U., Preffer, F. I. and Donahoe, P. K. (1999) Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin. Cancer Res. 5, 3488-3499
11. Stephen, A. E., Masiakos, P. T., Segev, D. L., Vacanti, J. P., Donahoe, P. K. and MacLaughlin, D. T. (2001) Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo. Proc. Natl. Acad. Sci. U.S.A. 98, 3214-3219
12. Stephen, A. E., Pearsall, L. A., Christian, B. P., Donahoe, P. K., Vacanti, J. P. and MacLaughlin, D. T. (2002) Highly purified Mullerian inhibiting substance inhibits human ovarian cancer in vivo. Clin. Cancer Res. 8, 2640-2646
13. Rey, R. A., Lhomme, C., Marcillac, I., Lahlou, N., Duvillard, P., Josso, N. and Bidart, J. M. (1996) Anti-Mullerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum α-inhibin and estradiol. Am. J. Obstet. Gynecol. 174, 958-965
14. Rey, R., Sabourin, J. C., Venara, M., Long, W. Q., Jaubert, F., Zeller, W. P., Duvillard, P., Chemes, H. and Bidart, J. M. (2000) Anti-Mullerian hormone is a specific marker of Sertoli- and granulosa-cell origin in gonadal tumors. Hum. Pathol. 31, 1202-1208
15. Baarends, W. M., van Helmond, M. J., Post, M., van der Schoot, P. J., Hoogerbrugge, J. W., de Winter, J. P., Uilenbroek, J. T., Karels, B., Wilming, L. G., Meijers, J. H. et al. (1994) A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the Mullerian duct. Development 120, 189-197
16. di Clemente, N., Wilson, C., Faure, E., Boussin, L., Carmillo, P., Tizard, R., Picard, J. Y., Vigier, B., Josso, N. and Cate, R. (1994) Cloning, expression, and alternative splicing of the receptor for anti-Mullerian hormone. Mol. Endocrinol. 8, 1006-1020
17. Imbeaud, S., Faure, E., Lamarre, I., Mattei, M. G., di Clemente, N., Tizard, R., Carre-Eusebe, D., Belville, C., Tragethon, L., Tonkin, C. et al. (1995) Insensitivity to anti-Mullerian hormone due to a mutation in the human anti-Mullerian hormone receptor. Nat. Genet. 11, 382-388
18. Gouedard, L., Chen, Y. G., Thevenet, L., Racine, C., Borie, S., Lamarre, I., Josso, N., Massague, J. and di Clemente, N. (2000) Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Mullerian hormone and its type II receptor. J. Biol. Chem. 275, 27973-27978
19. Visser, J. A., Olaso, R., Verhoef-Post, M., Kramer, P., Themmen, A. P. and Ingraham, H. A. (2001) The serine/threonine transmembrane receptor ALK2 mediates Mullerian inhibiting substance signaling. Mol. Endocrinol. 15, 936-945
20. Jamin, S. P., Arango, N. A., Mishina, Y., Hanks, M. C. and Behringer, R. R. (2002) Requirement of Bmpr1a for Mullerian duct regression during male sexual development. Nat. Genet. 32, 408-410
21. Clarke, T. R., Hoshiya, Y., Yi, S. E., Liu, X., Lyons, K. M. and Donahoe, P. K. (2001) Mullerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression. Mol. Endocrinol. 15, 946-959
22. Allard, S., Adin, P., Gouedard, L., di Clemente, N., Josso, N., Orgebin-Crist, M. C., Picard, J. Y. and Xavier, F. (2000) Molecular mechanisms of hormone-mediated Mullerian duct regression: involvement of β-catenin. Development 127, 3349-3360
23. Segev, D. L., Hoshiya, Y., Stephen, A. E., Hoshiya, M., Tran, T. T., MacLaughlin, D. T., Donahoe, P. K. and Maheswaran, S. (2001) Mullerian inhibiting substance regulates NFκB signaling and growth of mammary epithelial cells in vivo. J. Biol. Chem. 276, 26793-26806
24. Tsuji, M., Shima, H., Yonemura, C. Y., Brody, J., Donahoe, P. K. and Cunha, G. R. (1992) Effect of human recombinant Mullerian inhibiting substance on isolated epithelial and mesenchymal cells during Mullerian duct regression in the rat. Endocrinology 131, 1481-1488
25. Belville, C., Josso, N. and Picard, J. Y. (1999) Persistence of Mullerian derivatives in males. Am. J. Med. Genet. 89, 218-223
26. Teixeira, J. and Donahoe, P. K. (1996) Molecular biology of MIS and its receptors. J. Androl. 17, 336-341
27. Dutertre, M., Rey, R., Porteu, A., Josso, N. and Picard, J. Y. (1997) A mouse Sertoli cell line expressing anti-Mullerian hormone and its type II receptor. Mol. Cell. Endocrinol. 136, 57-65
28. Dutertre, M., Gouedard, L., Xavier, F., Long, W. Q., di Clemente, N., Picard, J. Y. and Rey, R. (2001) Ovarian granulosa cell tumors express a functional membrane receptor for anti-Mullerian hormone in transgenic mice. Endocrinology 142, 4040-4046
29. Racine, C., Rey, R., Forest, M. G., Louis, F., Ferre, A., Huhtaniemi, I., Josso, N. and di Clemente, N. (1998) Receptors for anti-Mullerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation. Proc. Natl. Acad. Sci. U.S.A. 95, 594-599
30. Lee, M. M., Seah, C. C., Masiakos, P. T., Sottas, C. M., Preffer, F. I., Donahoe, P. K., Maclaughlin, D. T. and Hardy, M. P. (1999) Mullerian-inhibiting substance type II receptor expression and function in purified rat Leydig cells. Endocrinology 140, 2819-2827
31. Baarends, W. M., Uilenbroek, J. T., Kramer, P., Hoogerbrugge, J. W., van Leeuwen, E. C., Themmen, A. P. and Grootegoed, J. A. (1995) Anti-Mullerian hormone and anti-Mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology 136, 4951-4962
32. Knebelmann, B., Boussin, L., Guerrier, D., Legeai, L., Kahn, A., Josso, N. and Picard, J. Y. (1991) Anti-Mullerian hormone Bruxelles: a nonsense mutation associated with the persistent Mullerian duct syndrome. Proc. Natl. Acad. Sci. U.S.A. 88, 3767-3771
33. Wilson, C. A., di Clemente, N., Ehrenfels, C., Pepinsky, R. B., Josso, N., Vigier, B. and Cate, R. L. (1993) Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-β superfamily. Mol. Endocrinol. 7, 247-257
34. Laune, D., Molina, F., Ferrieres, G., Villard, S., Bes, C., Rieunier, F., Chardes, T. and Granier, C. (2002) Application of the Spot method to the identification of peptides and amino acids from the antibody paratope that contribute to antigen binding. J. Immunol. Methods 267, 53-70
35. Sali, A. and Blundell, T. L. (1990) Definition of general topological equivalence in protein structures. A procedure involving comparison of properties and relationships through simulated annealing and dynamic programming. J. Mol. Biol. 212, 403-428
36. Mizuguchi, K., Deane, C. M., Blundell, T. L., Johnson, M. S. and Overington, J. P. (1998) JOY: protein sequence-structure representation and analysis. Bioinformatics 14, 617-623
37. Sali, A. and Blundell, T. L. (1993) Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815
38. Sippl, M. J. (1993) Recognition of errors in three-dimensional structures of proteins. Proteins 17, 355-362
39. Guex, N. and Peitsch, M. C. (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18, 2714-2723
40. Greenwald, J., Fischer, W. H., Vale, W. W. and Choe, S. (1999) Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase. Nat. Struct. Biol. 6, 18-22
41. Hart, P. J., Deep, S., Taylor, A. B., Shu, Z., Hinck, C. S. and Hinck, A. P. (2002) Crystal structure of the human TβR2 ectodomain-TGF-β3 complex. Nat. Struct. Biol. 9, 203-208
42. Thompson, T. B., Woodruff, T. K. and Jardetzky, T. S. (2003) Structures of an ActRIIB-activin A complex reveal a novel binding mode for TGf-β ligand-receptor interactions. EMBO J. 22, 1555-1566
43. Greenwald, J., Groppe, J., Gray, P., Wiater, E., Kwiatkowski, W., Vale, W. and Choe, S. (2003) The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol. Cell 11, 605-617
44. Teixeira, J., Kehas, D. J., Antun, R. and Donahoe, P. K. (1999) Transcriptional regulation of the rat Mullerian inhibiting substance type II receptor in rodent Leydig cells. Proc. Natl. Acad. Sci. U.S.A. 96, 13831-13838
45. Mendis-Handagama, S., Ariyaratne, H., Di Clemente, N. and Mrkonjich, L. (2004) Effects of luteinizing hormone and thyroid hormone on anti-Müllerian hormone receptor-type II expression in Leydig cells of prepubertal rats. Mol. Cell Endocrinol., in the press
46. Silverman, L. A. and Gitelman, S. E. (1996) Immunoreactive inhibin, Mullerian inhibitory substance, and activin as biochemical markers for juvenile granulosa cell tumors. J. Pediatr. 129, 918-921
47. Lane, A. H., Lee, M. M., Fuller, Jr, A. F., Kehas, D. J., Donahoe, P. K. and MacLaughlin, D. T. (1999) Diagnostic utility of Mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol. Oncol. 73, 51-55
48. Long, W. Q., Ranchin, V., Pautier, P., Belville, C., Denizot, P., Cailla, H., Lhomme, C., Picard, J. Y., Bidart, J. M. and Rey, R. (2000) Detection of minimal levels of serum anti-Mullerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J. Clin. Endocrinol. Metab. 85, 540-544
49. Scully, R. E., Young, R. H. and Clement, P. B. (1998) Sex chord-stromal tumors, granulosa tumors. In Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament (Rosai, J., ed.), pp. 169-188, Armed Forces Institute of Pathology (AFIP), Washington
50. Fox, H., Agrawal, K. and Langley, F. A. (1975) A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis. Cancer 35, 231-241
51. Pautier, P., Lhomme, C., Culine, S., Duvillard, P., Michel, G., Bidart, J. M., Gerbaulet, A. and Droz, J. P. (1997) Adult granulosa-cell tumor of the ovary: a retrospective study of 45 cases. Int. J. Gynecol. Cancer 7, 58-65
52. Gutowski, M., Carcenac, M., Pourquier, D., Larroque, C., Rouanet, P. and Pèlegrin, A. (2001) Intraoperative immunophotodetection for radical resection of cancer: evaluation in an experimental model. Clin. Cancer Res. 7, 1142-1148
53. Mach, J.-P., Pèlegrin, A. and Buchegger, F. (1991) Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors. Curr. Opin. Immunol. 3, 685-693
54. Chatal, J. F. and Hoefnagel, C. A. (1999) Radionuclide therapy. Lancet 354, 931-935